Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Enochian Biosciences Inc (ENOB)

Enochian Biosciences Inc (ENOB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 40,799
  • Shares Outstanding, K 58,284
  • Annual Sales, $ 0 K
  • Annual Income, $ -113,430 K
  • 60-Month Beta 1.09
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.59
Trade ENOB with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.08
  • Most Recent Earnings $-0.08 on 05/12/23
  • Latest Earnings Date 08/11/23
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4210 +66.27%
on 07/06/23
0.7638 -8.35%
on 08/01/23
+0.1966 (+39.05%)
since 07/03/23
3-Month
0.3928 +78.21%
on 06/29/23
1.2800 -45.31%
on 05/05/23
-0.5100 (-42.15%)
since 05/04/23
52-Week
0.3928 +78.21%
on 06/29/23
2.9900 -76.59%
on 08/08/22
-2.1000 (-75.00%)
since 08/04/22

Most Recent Stories

More News
Renovaro BioSciences (NASDAQ: RENB) Releases CEO Shareholder Message

Renovaro BioSciences (NASDAQ: RENB) (formerly NASDAQ: ENOB), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy, has released...

NVDA : 762.00 (-10.00%)
RENB : 2.17 (-5.65%)
ENOB : 0.7000 (unch)
Renovaro BioSciences (NASDAQ: RENB) CEO Featured in Recent Proactive Interview

Renovaro BioSciences (NASDAQ: RENB) (formerly NASDAQ: ENOB), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy, was featured...

RENB : 2.17 (-5.65%)
ENOB : 0.7000 (unch)
Renovaro BioSciences (NASDAQ: RENB) CEO Releases Shareholder Letter

Renovaro BioSciences (NASDAQ: RENB) (formerly NASDAQ: ENOB), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy, is sharing a...

RENB : 2.17 (-5.65%)
ENOB : 0.7000 (unch)
Renovaro BioSciences (NASDAQ: RENB) Enters Definitive Agreement to Combine with Leading AI Tech GEDi Cube

Renovaro BioSciences Inc. (NASDAQ: RENB) (formerly NASDAQ: ENOB), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy, has inked...

RENB : 2.17 (-5.65%)
ENOB : 0.7000 (unch)
Renovaro BioSciences (NASDAQ: RENB) Congratulates GEDiCube on New Joint Effort Clinical Trials

Renovaro BioSciences Inc. (NASDAQ: RENB) (formerly NASDAQ: ENOB), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy, released...

NVDA : 762.00 (-10.00%)
RENB : 2.17 (-5.65%)
ENOB : 0.7000 (unch)
Renovaro BioSciences (NASDAQ: RENB) Eyes Clear Path to IND Submission for Cancer Platform

Renovaro BioSciences (NASDAQ: RENB), (formerly NASDAQ: ENOB), announced that it remains confident in submitting an Investigational New Drug Application (“IND”) for its innovative Cancer Platform in...

RENB : 2.17 (-5.65%)
ENOB : 0.7000 (unch)
Renovaro BioSciences (NASDAQ: RENB) CEO Discusses Product Development in Letter to Shareholders

Renovaro BioSciences (NASDAQ: RENB), (formerly NASDAQ: ENOB), earlier this year issued a letter to shareholders from its CEO Mark Dybul, MD, in which Dr. Dybul discussed scientific and product development...

RENB : 2.17 (-5.65%)
ENOB : 0.7000 (unch)
Renovaro BioSciences (NASDAQ: RENB) Eyes Bright Future in Advancing Potentially Curative Therapies

Renovaro BioSciences (NASDAQ: RENB), (formerly NASDAQ: ENOB), is focused on advancing treatments for some of the world’s deadliest diseases. In late 2022, the company announced the award of a U.S. patent...

RENB : 2.17 (-5.65%)
ENOB : 0.7000 (unch)
Renovaro BioSciences (NASDAQ: RENB), GEDi Cube Announce LOI to Merge, Focus on Fight Against Cancer

Renovaro BioSciences Inc. (NASDAQ: RENB) (formerly NASDAQ: ENOB), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy, and...

INTC : 34.20 (-2.40%)
ORCL : 114.88 (-0.97%)
RENB : 2.17 (-5.65%)
ENOB : 0.7000 (unch)
FINAL DEADLINE ALERT: The Schall Law Firm Encourages Investors in Enochian Biosciences, Inc. with Losses of $100,000 to Contact the Firm

/PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Enochian Biosciences,...

ENOB : 0.7000 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Enochian BioSciences Inc. engages in the research and development, manufacturing and clinical trials of pharmaceutical and biological products for the human treatment of HIV and cancer. The company's product pipeline consists of ENO-1001, ENO-2001, ENO-3001, ENO-1002, ENO-5001 and ENO-4001. Enochian...

See More

Key Turning Points

3rd Resistance Point 0.7833
2nd Resistance Point 0.7667
1st Resistance Point 0.7333
Last Price 0.7000
1st Support Level 0.6833
2nd Support Level 0.6667
3rd Support Level 0.6333

See More

52-Week High 2.9900
Fibonacci 61.8% 1.9979
Fibonacci 50% 1.6914
Fibonacci 38.2% 1.3849
Last Price 0.7000
52-Week Low 0.3928

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar